SAFETY, IMMUNOGENICITY AND IMPACT ON PARASITE MULTIPLICATION RATES OF THE CANDIDATE BLOOD-STAGE VACCINE AMA1-C1/ALHYDROGEL WITH THE NOVEL ADJUVANT CPG 7909 AGAINST BLOOD-STAGE MALARIA CHALLENGE IN HEALTHY MALARIA-NAIVE VOLUNTEERS
Autores principales: | Duncan, C, Sheehy, S, Ewer, K, Douglas, A, Halstead, F, Edwards, N, Collins, K, Lillie, P, Poulton, I, Hunt-Cooke, A, Lawrie, A, Draper, S, Gilbert, S, Fay, M, Miura, K, Long, C, Wu, Y, Hill, A, Ellis, R |
---|---|
Formato: | Conference item |
Publicado: |
2010
|
Ejemplares similares
-
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
por: Duncan, C, et al.
Publicado: (2011) -
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
por: Christopher J A Duncan, et al.
Publicado: (2011-01-01) -
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
por: Gregory E D Mullen, et al.
Publicado: (2008-08-01) -
Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
por: Ruth D Ellis, et al.
Publicado: (2012-01-01) -
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
por: Ruth D Ellis, et al.
Publicado: (2010-01-01)